Sierra Oncology, Inc. Common Stock, also called Sierra Oncology, is a clinical stage drug development company of therapeutics for the treatment of cancer. Read More The firm focuses on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada. The listed name for SRRA is Sierra Oncology, Inc. Common Stock.